Sixi Wei

Publication Activity (10 Years)

Years Active: 2024-2024
Publications (10 Years): 5

Top Topics

Tyrosine Kinase

Signaling Pathway

Chronic Myeloid Leukemia

Top Venues

Molecular cancer therapeutics

This page only lists publications with an associated author ORCID identifier.

Publications

Weijie Ma, Sixi Wei, Qianping Li, Jie-Zeng Yu, Wenwu Xiao, Chihong Heidi Zhou, Ken Y Yoneda, Amir A Zeki, Tianhong Li
Simvastatin Overcomes Resistance to Tyrosine Kinase Inhibitors in Patient-derived, Oncogene-driven Lung Adenocarcinoma Models. Molecular cancer therapeutics 23 (5) (2024)
Weijie Ma, Sixi Wei, Qianping Li, Jie-Zeng Yu, Wenwu Xiao, Chihong Heidi Zhou, Ken Y Yoneda, Amir A Zeki, Tianhong Li
Simvastatin Overcomes Resistance to Tyrosine Kinase Inhibitors in Patient-derived, Oncogene-driven Lung Adenocarcinoma Models. Molecular cancer therapeutics 23 (5) (2024)
Weijie Ma, Sixi Wei, Qianping Li, Jie-Zeng Yu, Wenwu Xiao, Chihong Heidi Zhou, Ken Y Yoneda, Amir A Zeki, Tianhong Li
Simvastatin overcomes resistance to tyrosine kinase inhibitors in patient-derived, oncogene-driven lung adenocarcinoma models. Molecular cancer therapeutics (2024)
Weijie Ma, Sixi Wei, Qianping Li, Jie-Zeng Yu, Wenwu Xiao, Chihong Heidi Zhou, Ken Y Yoneda, Amir A Zeki, Tianhong Li
Simvastatin Overcomes Resistance to Tyrosine Kinase Inhibitors in Patient-derived, Oncogene-driven Lung Adenocarcinoma Models. Molecular cancer therapeutics 23 (5) (2024)
Weijie Ma, Sixi Wei, Qianping Li, Jie-Zeng Yu, Wenwu Xiao, Chihong Heidi Zhou, Ken Y Yoneda, Amir A Zeki, Tianhong Li
Simvastatin Overcomes Resistance to Tyrosine Kinase Inhibitors in Patient-derived, Oncogene-driven Lung Adenocarcinoma Models. Molecular cancer therapeutics 23 (5) (2024)